[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colon-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colon-cancer":32},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,143,0,25,[9,53,85,112,140,176,204,230,253,284,311,348,375,409,430,456,481,509,539,605,625,653,674,706,734],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":34,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100300428","phase-1-administering-peripheral-blood-lymphocytes-transduced-with-a-murine-t-cell-receptor-recognizing-the-g12v-variant-of-mutated-ras-in-hla-a1101-patients-100300428",false,"NCT03190941","Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","A Phase I\u002FII Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","* INCLUSION CRITERIA:\n* Measurable (per RECIST V1.1 criteria, metastatic, or unresectable malignancy expressing G12V mutated KRAS as assessed by one of the following methods: RT-PCR on tumor tissue, tumor DNA sequencing, or any other CLIA-certified laboratory test on resected tissue. Patients shown to have tumors expressing G12V mutated NRAS and HRAS will also be eligible as these oncogenes share complete amino acid homology with G12V mutated KRAS for their first 80 N-terminal amino acids, completely encompassing the target epitope.\n* Patients must be HLA-A\\*11:01 positive as confirmed by the NIH Department of Transfusion Medicine.\n* Confirmation of the diagnosis of cancer by the NCI Laboratory of Pathology.\n* Patients must have:\n\n  * previously received standard systemic therapy for their advanced cancer and have been either non-responders or have recurred, specifically:\n\n    * Patients with metastatic colorectal cancer must have had at least two systemic chemotherapy regimens that include 5FU, leucovorin, bevacizumab, oxaliplatin, and irinotecan (or similar agents), or have contraindications to receiving those medications.\n    * Patients with pancreatic cancer must have received gemcitabine, 5FU, and oxaliplatin (or similar agents), or have contraindications to receiving those medications.\n    * Patients with non-small cell lung cancer (NSCLC) must have had appropriate targeted therapy as indicated by abnormalities in ALK, EGFR, or expression of PDL- 1. Other patients must have had platinum-based chemotherapy.\n    * Patients with ovarian cancer or prostate cancer must have had approved first-line chemotherapy.\n\nOR\n\n* declined standard treatment\n* Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and asymptomatic are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for one month after treatment for the patient to be eligible. Patients\n\nwith surgically resected brain metastases are eligible.\n\n* Age greater than or equal to 18 years and less than or equal to 72 years.\n* Clinical performance status of ECOG 0 or 1\n* Patients must be willing to practice birth control from the time of enrollment on this study and 12 months after the last dose of combined chemotherapy for women and for 4 months after treatment for men.\n* Women of child-bearing potential must be willing to undergo pregnancy testing prior to the start of treatment because of the potentially dangerous effects of the treatment on the fetus.\n\nNOTE: Certain malignancies may secrete hormones that produce false positive pregnancy tests. Serial blood testing (e.g. HCG measurements) and\u002F or ultrasound may be performed for clarification.\n\n* Serology\n\n  * Seronegative for HIV antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive may have decreased immune-competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities.)\n  * Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative.\n* Hematology\n\n  * ANC greater than 1000\u002Fmm\\^3 without the support of filgrastim\n  * WBC greater than or equal to 2500\u002Fmm\\^3\n  * Platelet count greater than or equal to 80,000\u002Fmm\\^3\n  * Hemoglobin \\> 8.0 g\u002FdL. Subjects may be transfused to reach this cut-off.\n* Chemistry\n\n  * Serum ALT\u002FAST less than or equal to 5.0 times ULN\n  * Total bilirubin less than or equal to 2.0 mg\u002FdL, except in patients with Gilbert s Syndrome, who must have a total bilirubin less than 3.0 mg\u002FdL.\n* Patients must have either an eGFR \\> 60 mL\u002Fm (based on serum creatinine and lab nomogram) or a formal 6-24h CrCl \\> 60 mL\u002Fm.\n* Patients must have completed any prior systemic therapy at the time of enrollment.\n\nNote: Patients may have undergone minor surgical procedures or limited field radiotherapy within the four weeks prior to enrollment, as long as related major organ toxicities have recovered to less than or equal to grade 1.\n\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n* Willing to sign a durable power of attorney.\n* Subjects must be co-enrolled on protocol 03C0277.\n\nEXCLUSION CRITERIA:\n\n* Large volume pulmonary irradiation.\n* Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant.\n* Concurrent systemic steroid therapy.\n* Active systemic infections requiring anti-infective treatment, coagulation disorders, or any other active or uncompensated major medical illnesses.\n* Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).\n* Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune-competence may be less responsive to the experimental treatment and more susceptible to its toxicities.)\n* History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, or aldesleukin.\n* History of coronary revascularization or ischemic symptoms\n* For select patients with a clinical history prompting cardiac evaluation: last known LVEF less than or equal to 45%.\n* For select patients with a clinical history prompting pulmonary evaluation: known FEV1 less than or equal to 50% or DLCO less than 60%.\n* Patients who are receiving any other investigational agents.","ALL","18 Years","72 Years",{"count":21,"type":22},110,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","Background:\n\nA new cancer therapy involves taking white blood cells from a person, growing them in the lab, genetically modifying them, then giving them back to the person. This therapy is called gene transfer using anti-KRAS G12V mTCR cells.\n\nObjective:\n\nTo see if anti-KRAS G12 V mTCR cells are safe and can shrink tumors.\n\nEligibility:\n\nAdults at least 18 years old with cancer that has the KRAS G12V molecule on the surface of tumors.\n\nDesign:\n\nIn another protocol, participants will:\n\nBe screened\n\nHave cells harvested and grown\n\nHave leukapheresis\n\nIn this protocol, participants will have the procedures below.\n\nParticipants will be admitted to the hospital.\n\nOver 5 days, participants will get 2 chemotherapy medicines as an infusion via catheter in the upper chest.\n\nA few days later, participants will get the anti-KRAS G12V mTCR cells via catheter.\n\nFor up to 3 days, participants will get a drug to make the cells active.\n\nA day after getting the cells, participants will get a drug to increase their white blood cell count. This will be a shot or injection under the skin.\n\nParticipants will recover in the hospital for 1-2 weeks. They will have lab and blood tests.\n\nParticipants will take an antibiotic for at least 6 months.\n\nParticipants will have visits every few months for 2 years, and then as determined by their doctor.\n\nVisits will be 1-2 days. They will include lab tests, imaging studies, and physical exam. Some visits may include leukapheresis or blood drawn.\n\nParticipants will have blood collected over several years.\n\n...",[29,30,31,32,33],"Pancreatic Cancer","Gastric Cancer","Gastrointestinal Cancer","Colon Cancer","Rectal Cancer",[35,36,37,38,39],"KRAS","HRAS","NRAS","Cell Therapy","Immunotherapy","RECRUITING","2026-08-15",{"date":43,"type":44},"2026-08-18","ACTUAL",{"date":46,"type":44},"2017-09-21",{"date":48,"type":22},"2028-06-29",{"name":50,"class":51},"National Cancer Institute (NCI)","NIH",1,{"id":54,"slug":55,"hasResults":12,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":66,"conditions":67,"keywords":68,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":52},"100390472","d2-vs-d3-lymph-node-dissection-for-left-colon-cancer-100390472","NCT04364373","D2 vs D3 Lymph Node Dissection for Left Colon Cancer","D2 vs D3 Lymph Node Dissection for Left Colon Cancer: Multicenter Randomize Control Trial (DILEMMA)","DILEMMA","Inclusion Criteria:\n\n1. Agreement of the patient to participate in trial\n2. Colon cancer (only adenocarcinoma )\n3. The tumor located between the splenic flexure and rectosigmoid junction\n4. cT3-Т4а,b\n5. cN0-2\n6. cM0\n7. Tolerance of chemotherapy\n8. ASA 1-3\n\nExclusion Criteria:\n\n1. сТis - Т2, сТ4b (tail of the pancreas, stomach, small bowel, ureter, urinary bladder)\n2. Preoperative complications of the tumor (perforation and full bowel 3. obstruction)\n3. Previous radiotherapy or chemotherapy\n4. Synchronous or metachronous tumors\n5. Women during Pregnancy or breast feeding period","75 Years",{"count":63,"type":22},1381,[65],"NA","The efficiency of the D3 lymph node dissection is still controversial for left colon cancer patients. This study will try find difference in 5-year overall survival between D2 and D3 lymph node dissection. Investigation of the functional and short-term outcomes will clarify safety of the D3 lymph node dissection.",[32],[69,70,71,72,73,74],"D2","D3","lymph node dissection","complete mesocolic excision","left colon cancer","CME","2026-08-14",{"date":77,"type":44},"2026-08-17",{"date":79,"type":44},"2020-03-31",{"date":81,"type":22},"2033-12-31",{"name":83,"class":84},"Russian Society of Colorectal Surgeons","OTHER",{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":12,"sex":17,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":105,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":52},"100254821","genomic-services-research-program-100254821","NCT02595957","Genomic Services Research Program","* ELIGIBILITY CRITERIA:\n\nWe employ a referral form through SurveyMonkey to receive referrals from recruitment partners or self-referrals. This serves as an intake form and self-reported eligibility review. This form asks for contact information, key information about the prospective participant s SF,\n\nand subjective understanding of their result.\n\nIf we conclude, based on a review of the SF and available personal and\u002For family history, that the pathogenicity of the SF is not at least likely pathogenic, that participant may be eligible for the survey, interview, and\u002For re-contact for future follow-up, but will not complete any other protocol procedures (such as cascade testing). If a participant is consented and information arises during the social and behavioral study procedures that lead study staff to believe the genetic result does not qualify as an SF, the participant will be\n\nconsidered a screen failure and will not continue with study procedures.\n\nWe plan to offer enrollment in this protocol to English- or Spanish-speaking recipients of SF. We do not have trained staff who can conduct the interviews in languages other than English and Spanish.\n\nIf a caregiver of a minor or adult who is unable to consent is enrolled as an index participant to complete the survey and interview on behalf of the SF recipient, they may also be eligible for cascade testing to relate presence of an SF-related phenotype in a family member with presence or absence of SF genotype.\n\n-We may enroll a child in this protocol if he\u002Fshe is the only person in his\u002Fher family who has the SF, is symptomatic of the disease, or is in the age range to receive screening for the disease (e.g., Wilson disease and familial hypercholesterolemia have childhood onset).\n\nWe will not enroll neonates (less than one month old).\n\n* We may enroll adults who are unable to consent (i.e., an individual who is impaired at the time of consent) in this protocol if he\u002Fshe is the only person in his\u002Fher family who has the SF, is symptomatic of the disease, or is in the age range to receive screening for the disease.\n* We may enroll women who are pregnant in this protocol and women who become pregnant during the study can continue their participation. We will not perform prenatal genetic testing.\n* NIH staff members are not prohibited from enrollment if they meet the study s eligibility criteria. The study team will make every effort to protect the confidentiality of the NIH staff member s health information, to minimize any pressure on or discomfort of the NIH staff\n\nmember and provide a copy of the NIH Frequently Asked Questions (FAQs) for Staff Who are Considering Participation in NIH Research , before consent is obtained.","1 Month","105 Years",{"count":94,"type":22},5000,"OBSERVATIONAL","Background:\n\nGenes are the instructions a person s body uses to function. Genome sequencing reads through all of a person s genes. Everyone has many gene variants, and most do not cause disease. Some gene variants called secondary findings may be important for a person s health even if they are not related to the reason why a person had genome sequencing done. Researchers want to learn more about what it means to have a secondary finding.\n\nObjectives:\n\nTo learn about how gene variants may affect a person s health.\n\nTo learn about how people understand their genetic test results.\n\nEligibility:\n\nPeople with secondary findings from genetic testing done as part of a research study, clinical care, or other methods.\n\nDesign:\n\nParticipants may be asked to do an online survey and phone interview to ask what they think about their results, their healthcare, and if they talk with their family about the result.\n\nEligible participants may be offered a visit to the NIH Clinical Center where they will be evaluated for health problems related to the secondary finding.\n\nDNA samples that were already collected may be studied.\n\nParticipants may be asked to send in a second DNA sample (blood or saliva). These will be used to verify any findings.\n\nParticipants who have a secondary finding can get genetic counseling.",[32,98],"Breast Cancer",[100,101,102,103,104],"Genome Sequencing","Secondary Findings","Return of Results","Natural History","Exome Sequencing",{"date":77,"type":44},{"date":107,"type":44},"2014-09-16",{"date":109,"type":22},"2028-12-31",{"name":111,"class":51},"National Human Genome Research Institute (NHGRI)",{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":119,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":122,"conditions":123,"keywords":127,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":4,"leadSponsor":139,"locationsCount":52},"100060621","collection-of-blood-from-patients-with-cancer-100060621","NCT00034216","Collection of Blood From Patients With Cancer","Biospecimen Acquisition From Human Subjects","* INCLUSION CRITERIA:\n\nPatients with a known or suspected malignancy and healthy volunteers 18 years of age and older are eligible.\n\nPerformance status of ECOG 0, 1, 2, or 3 for admission to this protocol.\n\nAbility to understand and the willingness to sign a written informed consent document.\n\nINCLUSION FOR APHERESIS:\n\nNote: Effective with Amendment CC, participants will no longer be asked to undergo apheresis. This content is being retained for historical reference.\n\nHemoglobin greater than or equal to 10 mg\u002FdL and platelet count \\> 75,000\u002Fmm(3)\n\nWeight greater than 25 kg\n\nHIV negative\n\nProthrombin Time - within normal limits\n\nPartial Thromboplastin Time - within normal limits\n\nMedically indicated central line in place or adequate peripheral venous access\n\nEXCLUSION CRITERIA:\n\nNone.",true,{"count":121,"type":22},1750,"This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. This study does not involve treatment.\n\nParticipants will have about 50 ml (3 tablespoonfuls) of blood drawn. Depending on their condition, patients may be invited to enroll in a clinical research study involving chemotherapy, radiotherapy, or surgery. Additional 40-ml blood samples may be drawn during the course of treatment.",[124,98,32,125,126],"Prostate Cancer","Lung Cancer","Liver Cancer",[128,129,130,103,131,132,133],"Suppressor Cells","T-cells","CD4+ \u002F CD25+ cells","Cancer","Malignancy","Blood Sample","2026-08-12",{"date":136,"type":44},"2026-08-13",{"date":138,"type":44},"2002-07-16",{"name":50,"class":51},{"id":141,"slug":142,"hasResults":12,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":150,"briefSummary":151,"conditions":152,"keywords":162,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":175},"100647108","a-study-of-shy-onc6-a-novel-proteasome-inhibitor-in-adults-with-advanced-or-metastatic-solid-tumors-100647108","NCT07705334","A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors","A Phase 1 Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SHY-ONC6 in Participants With Advanced or Metastatic Solid Tumors","Luca-1","Inclusion Criteria:\n\n* Male or female ≥18 years of age.\n* Life expectancy \\>3 months.\n* ECOG performance status 0-1.\n* Histologically\u002Fcytologically confirmed advanced or metastatic solid tumors that have progressed on or are intolerant\u002Funsuitable for standard therapies. Eligible tumor types: TNBC, HR+ breast cancer, colon cancer, gastric cancer, HCC, NSCLC (adeno and squamous), mesothelioma, pancreatic cancer, HRPC, soft tissue sarcoma; other tumor types after Medical Monitor discussion. Stable CNS metastases ≥4 weeks post-radiotherapy and off steroids ≥14 days are permitted.\n* ≥1 measurable lesion per RECIST v1.1 (prostate cancer with bone-only disease and elevated PSA assessed by PCWG3).\n* Accessible tumor for biopsy\n* Adequate organ\u002Fbone marrow function.\n* Willingness and ability to provide informed consent.\n* Negative serum pregnancy test and use of effective contraception through 90 days after last dose for women of childbearing potential.\n* Male participants must use barrier contraception or abstinence and not donate sperm through 90 days after last dose.\n\nExclusion Criteria:\n\n* High-risk cardiovascular disease.\n* Concurrent anti-cancer treatment.\n* Active infection requiring systemic treatment within 2 weeks pre-dose.\n* History of another malignancy (with standard exceptions for in situ disease, non-melanoma skin cancers, and remission ≥2 years).\n* Active HBV (HBV-DNA \\>ULN), HCV (HCV-RNA \\>ULN), or HIV (well-controlled HIV with CD4 ≥350 cells\u002FµL and undetectable viral load permitted); AIDS-defining opportunistic infection within 12 months.\n* Compromised pulmonary function within 6 months pre-dose .\n* Pregnancy or breastfeeding.\n* Recent radiotherapy, systemic anti-tumor therapy, other investigational therapy without appropriate washout.\n* Major surgery ≤4 weeks pre-dose.\n* Unable to swallow tablets or conditions affecting GI absorption.\n* Any medical or psychiatric disorders affecting compliance and\u002For interpretation of study results.\n* Persistent toxicities from prior anti-cancer therapy (exceptions apply)\n* Clinically significant corneal disease.\n* Unable to comply with prohibited concomitant medication restrictions.",{"count":149,"type":22},30,[25],"This is a Phase 1, first-in-human (FIH), open-label, multicenter study designed to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SHY-ONC6 in participants with advanced or metastatic solid tumors who have progressed on or are intolerant to standard therapies. The study will consist of 2 parts: a dose escalation part (Phase 1a) and a dose expansion part (Phase 1b).",[153,154,155,32,30,156,157,158,159,160,161],"Advanced or Metastatic Solid Tumors","Triple Negative Breast Cancer (TNBC)","HR+ Breast Cancer","Hepatecellular Carcinoma","NSCLC (Advanced Non-small Cell Lung Cancer)","Mesothelioma","Pancreatic Carcinoma Metastatic","Hormone Refractory Prostate Cancer","Soft Tissue Sarcomas",[163,164],"Proteasome Inhibitor","Solid Tumors","2026-08-06",{"date":167,"type":44},"2026-08-10",{"date":169,"type":44},"2026-06-24",{"date":171,"type":22},"2028-05-15",{"name":173,"class":174},"SHY Therapeutics","INDUSTRY",4,{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":185,"briefSummary":186,"conditions":187,"keywords":191,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":203},"100602773","phase-1-a-study-of-phn-012-in-patients-with-advanced-solid-tumors-100602773","NCT07127874","A Study of PHN-012 in Patients With Advanced Solid Tumors","First-in-Human, Phase 1 Study of PHN-012, an Antibody Drug Conjugate, in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n* Has histologically confirmed, advanced\u002Fmetastatic:\n\n  1. Colorectal adenocarcinoma (CRC), or\n  2. Non-small cell lung cancer (NSCLC), or\n  3. Pancreatic ductal adenocarcinoma (PDAC).\n* Has received at least one prior systemic therapy and radiologically or clinically determined progressive disease during or after the most recent line of therapy, and for whom no further standard therapy is available or who is intolerant to standard therapy.\n* Has measurable disease.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Has adequate organ function.\n* Has available tumor tissue sample at screening (either an archival specimen or fresh biopsy material).\n\nExclusion Criteria:\n\n* Had prior treatment with any ADC containing topoisomerase-1 inhibiting payload.\n* Has unstable central nervous system metastasis.\n* Has persistent toxicities from previous systemic anti-cancer treatments of Grade \\>1.\n* Has received systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of the study drug.\n* Has received wide-field radiotherapy (\\> 30% of marrow-bearing bones) within 28 days, or focal radiation for analgesic purpose or for lytic lesions at risk of fracture within 14 days prior to first dose of the study drug, or no recovery from side effects of such intervention.\n* Had major surgery (not including placement of vascular access device or tumor biopsies) within 28 days prior to first dose of the study drug, or no recovery from side effects of such intervention.\n* Has a history of non-infectious pneumonitis (NIP) \u002F interstitial lung disease (ILD) requiring systemic steroids within 6 months prior to first dose of the study drug, active NIP \u002F ILD or suspected NIP \u002F ILD which cannot be ruled out by imaging for Screening.",{"count":184,"type":22},165,[25],"This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.",[32,29,188,189,190],"Lung Cancer (NSCLC)","Advanced Cancer","Advanced Solid Tumors",[192,193,131,194],"Antibody Drug Conjugate","Carcinoma","Solid Tumor","2026-08-05",{"date":165,"type":44},{"date":198,"type":44},"2025-09-23",{"date":200,"type":22},"2028-05",{"name":202,"class":174},"Pheon Therapeutics",26,{"id":205,"slug":206,"hasResults":12,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":12,"sex":17,"minAge":212,"maxAge":61,"enrollmentInfo":213,"targetDuration":4,"studyType":23,"phases":215,"briefSummary":217,"conditions":218,"keywords":219,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":222,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":229},"100480292","platform-study-of-circulating-tumor-dna-directed-adjuvant-chemotherapy-in-colon-cancer-kcsg-co22-12-100480292","NCT05534087","Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)","A Randomized Controlled Phase III Trial of Treatment Intensification in Stage II-III Colon Cancer Patients With Positive MRD During Adjuvant Chemotherapy","CLAUDIA","Inclusion Criteria:\n\n1. Patients who willingly consented and signed the informed consent form to participate in the study\n2. Age range of 19 to 75 years\n3. Adenocarcinoma of colon confirmed by histology\n4. Patients with stage II-III colon cancer as defined by the American Joint Committee on Cancer's eighth edition (Stage II cancer is limited to patients who are at a high risk, with more than one risk factor for recurrence.)\n5. Patients who have completed the sixth cycle of FOLFOX or the fourth cycle of CAPOX adjuvant chemotherapy for colon cancer following radical resection (R0 resection)\n6. A ctDNA test performed 3 to 6 weeks after surgery reveals a positive MRD\n7. ECOG performance scale of 0-1 (only 1 is allowed for 70-75 years old)\n8. Adequate bone marrow function \\[ANC ≥1,300\u002FLL, platelets ≥75,000\u002FLL, hemoglobin ≥8.0g\u002FdL (may be eligible in study if intermittent transfusion is required)\\]\n9. Appropriate liver function (total bilirubin ≤1.5xULN, AST and ALT ≤3xULN)\n10. Appropriate renal function (serum creatine ≤1.5xULN, renal clearance rate ≥50 ml\u002Fmin)\n11. Patients who are deemed to understand the study protocol and are willing to participate in the trial until it is completed\n\nExclusion Criteria:\n\n1. Pregnant or lactating women\n2. Pregnant women who had a positive pregnancy test at the time of the baseline examination (postmenopausal women must be amenable for at least 12 months to be considered non-fertility)\n3. Sexually active men and women of reproductive age who are unwilling to use contraception throughout the study treatment and for a period of 6 months (female) or 3 months (male) following the discontinuation of study treatment\n4. Clinically significant heart condition \\[unstable angina requiring medication, symptomatic coronary artery disease, congestive heart failure, or significant heart arrhythmia above NYHA II, or acute coronary syndrome, including myocardial infarction within the last 6 months\\]\n5. Active viral infections such as HIV (However, HBV carriers may enroll if their HBV DNA titer is less than 20,000 IU\u002Fml, and antiviral drugs for hepatitis B may be administered prophylactically at the investigator's discretion)\n6. Significant uncontrolled infections or other uncontrolled comorbidities\n7. Symptomatic inflammatory bowel disease\n8. Allogeneic transplantation history necessitating immunosuppressive therapy\n9. A history of other malignancies identified within the last three years, except for completed removed basal cell carcinoma of the skin, completely removed cervical epithelial carcinoma, and thyroid cancer that has been treated, including surgery\n10. Recurrent or residual disease identified clinically or radiographically\n11. Previous history of irinotecan treatment\n12. Polyposis including familial adenomatous polyps\n13. Two or more colon or rectal cancers with a pathologic stage greater than II that were detected concurrently or within the last three years\n14. When the investigator determines that the subjects' safety may be jeopardized during the study because of other serious or unstable pre-existing medical or mental conditions\n15. Prior clinical trial participation and usage of investigational drugs or devices following radical resection of colon cancer\n16. Patients with peripheral neuropathy who have a CTCAE v5 grade 3 or higher functional disability (corresponds to \"severe symptoms, limiting self-care activity of daily living\" according to CTCAE v5 criteria)\n17. Previous anaphylactic reaction or severe and unexpected reactions to fluoropyrimidines or platinum\n18. Gilbert's syndrome, dehydro-pyridine dehydrogenase (DPD) deficiency, or homozygous UGT1A1\\*28 alleles","19 Years",{"count":214,"type":22},236,[216],"PHASE3","This study is a prospective, open-label, randomized phase 3 clinical trial. It aims to investigate if the early introduction of intensified chemotherapy (3 months of modified FOLFIRINOX) improves the 3-year disease-free survival rate compared to standard treatment (FOLFOX\u002FCAPOX for an additional three months to complete six months of standard adjuvant chemotherapy) in patients with stage 2-3 colon cancer in whom ctDNA MRD in the part 1 study remained positive during adjuvant FOLFOX\u002FCAPOX chemotherapy",[32],[220,221],"Minimal residual disease","Intensified chemotherapy",{"date":167,"type":44},{"date":224,"type":44},"2022-12-15",{"date":226,"type":22},"2030-09-30",{"name":228,"class":84},"Seoul National University Hospital",13,{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":237,"targetDuration":239,"studyType":95,"phases":4,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":244,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":4},"100650323","radiogenomic-profiling-of-dendritic-cells-and-macrophages-to-predict-recurrence-in-colorectal-liver-metastasis-100650323","NCT07744139","Radiogenomic Profiling of Dendritic Cells and Macrophages to Predict Recurrence in Colorectal Liver Metastasis","RaP-DMac-LiMe","Inclusion Criteria:\n\n* Age ≥18 years.\n* Histologically confirmed colorectal liver metastases.\n* Administration of neoadjuvant chemotherapy prior to liver resection, with objective tumour response classified as partial response (PR) or stable disease (SD) according to RECIST criteria.\n* Availability of a hepatobiliary contrast-enhanced MRI performed within 2 months before surgery.\n* Provision of informed consent for prospectively enrolled participants, or eligibility under Article 110-bis of the Italian Privacy Code for retrospectively enrolled participants.\n\nExclusion Criteria:\n\n* Recurrent metastatic disease.\n* Liver resection performed with non-curative intent.\n* Current or previous hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.\n* Concomitant malignancies or history of another malignancy treated within the previous 5 years.",{"count":238,"type":22},210,"24 Months","The RaP-DMac-LiMe study (Radiogenomic Profiling of Dendritic Cells and Macrophages to Predict Recurrence in Colorectal Liver Metastasis) is a monocentric, non-profit observational study promoted by Fondazione Policlinico Universitario A. Gemelli IRCCS. Its primary aim is to identify immunological, genomic, and radiomic biomarkers associated with recurrence risk in patients with colorectal liver metastases (CRLM) undergoing curative-intent liver resection.\n\nThe study is based on the need to improve prognostic stratification in CRLM by integrating information from the tumor immune microenvironment, tumor genomics, radiomics, and clinical data. Particular attention is given to myeloid immune cells, especially dendritic cells and tumor-associated macrophages, whose role in metastatic progression and recurrence remains insufficiently understood.\n\nThe primary objective is to assess the association between myeloid immune profiles and recurrence risk through integrated molecular, spatial, genomic, and radiological analyses. Secondary objectives include characterizing the transcriptomic and genomic features of dendritic cells and macrophages, identifying radiomic and circulating tumor DNA (ctDNA) biomarkers, and evaluating their potential as non-invasive tools for recurrence prediction and patient stratification.\n\nThe study includes a retrospective cohort of approximately 160 patients treated between 2009 and 2023 and a prospective cohort of approximately 50 patients who will be followed for 24 months. Tumor tissue samples, peripheral blood, imaging data (CT\u002FMRI), and clinical information collected during routine care will be analyzed without introducing any experimental interventions or deviations from standard clinical practice.\n\nAnalyses will include transcriptomic profiling, multiplex spatial characterization of immune cells, circulating tumor DNA sequencing using next-generation sequencing technologies, radiomic feature extraction, and integration of all data using statistical and machine learning approaches. Predictive models will be trained on retrospective data and independently validated in the prospective cohort.\n\nThe primary endpoint is the prediction of colorectal liver metastasis recurrence within two years after liver resection. Ultimately, the study aims to develop and validate a multimodal predictive model integrating immune, genomic, radiomic, and clinical variables to improve recurrence risk assessment and support personalized patient management.\n\nThe overall study duration is 36 months. All procedures will be conducted in accordance with ethical standards and data protection regulations, with samples and clinical data pseudonymized and handled in compliance with the GDPR.",[242,243,32],"Colo-rectal Cancer","Liver Metastases","NOT_YET_RECRUITING","2026-08-04",{"date":165,"type":44},{"date":248,"type":22},"2026-09-01",{"date":250,"type":22},"2029-12-31",{"name":252,"class":84},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":23,"phases":262,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":276,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":283},"100597545","distance-based-exercise-to-preserve-function-and-prevent-disability-100597545","NCT07059884","Distance-Based Exercise to Preserve Function and Prevent Disability","DEFEND","Inclusion Criteria:\n\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must have histologically confirmed diagnosis of one of the following cancers: anus, bladder, breast, cervix, colon\u002Frectum, endometrium, esophagus, gallbladder, head\u002Fneck, kidney, liver, lung, ovary, pancreas, prostate, sarcoma, stomach\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must be initiating outpatient cytotoxic chemotherapy for curative intent of at least 10 weeks duration (with or without concurrent radiation, immunotherapy, or other targeted therapy). Patients must be enrolled and baseline measures collected on or before administration of their second cycle of cytotoxic therapy. Patients receiving outpatient cytotoxic chemotherapy for curative intent in the neoadjuvant or adjuvant setting are eligible. Patients receiving definitive chemoradiation for the tumors listed above, are also eligible. Regimens of immunotherapy or monoclonal antibodies ONLY are not eligible\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Age 18-64 years\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have metastatic cancer\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of severe cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity. Examples would include unstable angina, recent myocardial infarction, oxygen-dependent pulmonary disease, and osteoarthritis requiring imminent joint replacement. Moderate arthritis that does not preclude physical activity is not a reason for ineligibility\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot be pregnant, because this study involves remotely delivered exercise, and cannot be breast-feeding as patients must be receiving cytotoxic chemotherapy, during which breast-feeding is contraindicated\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of current alcohol, substance abuse, or dementia\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Engaged in full time gainful employment of at least 30 hours per week at the time of cancer diagnosis\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Currently no self-report of engagement in competitive sports (e.g. not training for running races, triathlons, etc.) AND no self-report of twice weekly progressive resistance exercise training for at least 3 consecutive months within the past year\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Self-reported ability to walk for 6 minutes (use of assistive devices will be allowed)\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Not participating in another weight loss, physical activity, or dietary intervention clinical trial\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Predicted 6MWT distance of 550 meters or less\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Concurrent enrollment in treatment or supportive care trials (other than those focused on weight loss or exercise) is allowed with the permission of the Alliance Executive Officer and both studies' study chairs\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Eligibility is restricted to individuals who can comprehend and read English given that participation in the study will require the ability to read intervention materials and work with a coach through telehealth sessions\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): The trial is unable to accommodate the needs of deaf or blind participants as the study relies on language and visualization of exercise through telehealth sessions\n* CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Clinicians and research staff from enrolling sites who meet following criterion will be deemed eligible to participate as a clinical stakeholder:\n\n  \\* Providing clinical care for participating patients on this study\n* CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Ability to speak and understand English\n\nExclusion Criteria:\n\n\\-",{"count":261,"type":22},104,[65],"This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side effects can make it difficult to work, take care of family, and do other things the patient wants to do. Preliminary research shows that exercise can help prevent some of these side effects, but it can be more difficult to start an exercise program when a patient is receiving cancer treatment. The exercise program in this study is delivered through telehealth (TH) video calls. The TH sessions are delivered by trained staff that supervise resistance exercises. The trained staff also provide guidance to the patient on completing unsupervised aerobic sessions on their own. This may be a successful way to deliver an exercise program and make it easier for cancer patients to exercise in their own home during treatment.",[265,266,267,98,268,32,269,270,271,30,272,126,125,273,274,29,124,33,275],"Localized Malignant Solid Neoplasm","Anal Cancer","Bladder (Urothelial, Transitional Cell) Cancer","Cervical Cancer","Endometrial Cancer","Esophageal Cancer","Gall Bladder Cancer","Kidney Cancer","Head and Neck Cancer","Ovarian Cancer","Sarcoma",{"date":195,"type":44},{"date":278,"type":44},"2026-02-11",{"date":280,"type":22},"2027-08-31",{"name":282,"class":84},"Alliance for Clinical Trials in Oncology",18,{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":23,"phases":293,"briefSummary":294,"conditions":295,"keywords":296,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":52},"100589030","phase-2-radiotherapy--systemic-therapy-as-conversion-therapy-for-pmmrmss-t4m0-colon-cancerneo-color-100589030","NCT06949111","Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR\u002FMSS T4M0 Colon Cancer（Neo-Color）","Efficacy and Safety of Conversion Therapy for pMMR\u002FMSS T4M0 Colon Cancer Patients Treated With Radiotherapy and Systemic Therapy: a Prospective, Open-label, Multi-center, Randomized Controlled Trial（Neo-Color）","Inclusion Criteria:\n\n1. Age ≥18 years, no restriction on gender.\n2. ECOG performance status of 0-1.\n3. Histopathologically confirmed diagnosis of colon adenocarcinoma (including mucinous adenocarcinoma), identified as pMMR\u002FMSS type; the primary tumor site must be specified (left colon defined as from the splenic flexure to the rectosigmoid junction, right colon defined as from the cecum to the proximal splenic flexure).\n4. Baseline imaging (enhanced CT\u002FMRI) confirms clinical staging as cT4NanyM0 according to the AJCC 8th edition staging criteria.\n5. Laboratory criteria prior to enrollment must meet the following ranges:\n\n(1) Hematology: Absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL, platelets ≥ 100 × 10\\^9\u002FL, hemoglobin ≥ 90 g\u002FL.\n\n(2) Liver and renal function: ALT\u002FAST ≤ 2.5 × ULN, total bilirubin ≤ 1.5 × ULN, creatinine ≤ 1.5 × ULN or creatinine clearance rate ≥ 60 mL\u002Fmin (Cockcroft-Gault formula).\n\n(3) Coagulation function: INR ≤ 1.5, APTT ≤ 1.5 × ULN (for those not on anticoagulation therapy).\n\n6.Women of childbearing potential and men must agree to use effective contraception during the study and for 6 months after the last treatment.\n\n7.Willingness to sign a written informed consent form and commit to completing the entire treatment and follow-up plan.\n\nExclusion Criteria:\n\n1. Histological type of neuroendocrine carcinoma, squamous cell carcinoma, or other non-adenocarcinoma components comprising more than 50%.\n2. Presence of distant metastasis (including peritoneal metastasis, non-regional lymph node metastasis, or organ metastasis).\n3. Previous radiotherapy, chemotherapy, targeted therapy, or immunotherapy for colon cancer.\n4. Active autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis requiring long-term immunosuppressive therapy).\n5. Active infections (e.g., HIV, positive HBV\u002FHCV viral load requiring antiviral treatment for stabilization).\n6. Severe cardiovascular diseases (e.g., myocardial infarction within 6 months, unstable angina, uncontrolled hypertension \\>160\u002F100 mmHg).\n7. History of other malignancies (except for cured non-melanoma skin cancer, cervical carcinoma in situ, etc., with a disease-free period of ≥5 years).\n8. Uncontrolled diabetes (HbA1c \\> 8%) or thyroid dysfunction (TSH outside the normal range requiring medication).\n9. Severe chronic bowel diseases (e.g., active Crohn's disease, ulcerative colitis).\n10. History of radiation enteritis or extensive abdominal adhesions affecting radiotherapy target delineation.\n11. Unrecovered bone marrow suppression (ANC \\\u003C 1.5 × 10\\^9\u002FL, PLT \\\u003C 100 × 10\\^9\u002FL, Hb \\\u003C 90 g\u002FL).\n12. Liver function with Child-Pugh score ≥ B or renal function with eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 m².\n13. Pregnant or breastfeeding women (blood\u002Furine HCG test required during screening).\n14. Cognitive impairment or history of psychiatric disorders affecting treatment compliance.\n15. Concurrent participation in other interventional clinical trials.\n16. Patients deemed unsuitable for participation by the investigator.",{"count":292,"type":22},128,[26],"The goal of this clinical trial is to evaluate the efficacy and safety of conversion therapy using radiotherapy combined with systemic treatment (chemotherapy + immune checkpoint inhibitors) for patients with pMMR\u002FMSS T4M0 stage colon cancer. The main questions it aims to answer are:\n\n1. Can the combination of radiotherapy and systemic treatment improve the R0 resection rate and complete response (CR) rate compared to chemotherapy alone?\n2. Does this combination therapy enhance the tumor immune microenvironment, leading to better long-term outcomes?\n\nResearchers will compare the experimental group receiving concurrent chemoradiotherapy (CCRT) followed by 4 cycles of CAPOX + Iparomlimab and Tuvonralimab Injection with the control group receiving 4 cycles of CAPOX alone to see if the combination therapy offers superior efficacy.\n\nParticipants will:\n\n1. Undergo preoperative CCRT combined with one cycle of Iparomlimab and Tuvonralimab Injection, followed by 4 cycles of CAPOX + Iparomlimab and Tuvonralimab Injection in the experimental group.\n2. Receive 4 cycles of CAPOX in the control group.\n3. After the initial treatment regimen, surgical candidates will undergo surgery followed by an additional 4 cycles of CAPOX. Non-surgical candidates will continue with 4 more cycles of CAPOX, completing a total of 8 cycles. Efficacy will be re-evaluated after the completion of 8 cycles.",[32],[297,298,299,300,301],"Locally advanced colon cancer","Neoadjuvant chemoradiotherapy","Immune checkpoint inhibitors","Complete response rate","Radiotherapy","2026-07-30",{"date":304,"type":44},"2026-08-03",{"date":306,"type":44},"2025-05-15",{"date":308,"type":22},"2030-03",{"name":310,"class":84},"Hebei Medical University Fourth Hospital",{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":4,"eligibilityCriteria":317,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":23,"phases":320,"briefSummary":321,"conditions":322,"keywords":329,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":347},"100617629","phase-1-a-study-to-investigate-the-safety-tolerability-pharmacokinetics-and-anti-tumor-activity-of-cbi-1214-t-cell-engager-in-participants-with-advanced-or-metastatic-mssmsi-l-colorectal-cancer-100617629","NCT07321106","A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS\u002FMSI-L Colorectal Cancer","A Phase 1, First-in-human (FIH), Dose-Escalation and Dose-Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic Microsatellite Stable (MSS)\u002FMicrosatellite Instability Low (MSI-L) Colorectal Cancer","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Participant with MSS\u002FMSI-L CRC, who has exhausted at least one prior line of standard systemic therapy for their current malignancy.\n* Participant with genomic aberrations, including but not limited to BRAFV600E mutations and HER2 amplifications, for which FDA-approved targeted therapies are available, must:\n\n  * Have received prior treatment with applicable FDA-approved targeted therapies AND\n  * Either have experienced disease progression, be refractory, or be intolerant to directed molecular therapy.\n* Participant able to provide archival tissue sample or fresh biopsy tissue sample\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Participant whose CRC tumor tissues have been identified as dMMR or MSI-H\n* Known history of solid organ or tissue transplant; history of interstitial lung disease or non-infectious pneumonitis.\n* Untreated central nervous system (CNS) metastatic disease.\n* Active autoimmune disease that has required systemic treatment within the past 2 years (participants with hormone replacement therapy for adequately controlled endocrinopathy are allowed in the study).\n* History of recent infection (within 4 weeks of C1D1) considered to be caused by one of the pathogens: HSV1, HSV2, VZV, EBV, CMV, measles, Influenza A, Zika virus, Chikungunya virus, mycoplasma pneumonia, Campylobacter jejuni, or enterovirus D68.\n* Known seropositive for human immunodeficiency virus, hepatitis B surface antigen, or antibody to hepatitis C virus with confirmatory testing and requiring anti-viral therapy.\n* History of Steven's Johnson's syndrome or toxic epidermal necrolysis syndrome.\n* Significant medical comorbidities, including uncontrolled hypertension (diastolic blood pressure \\>115 mm Hg), unstable angina, congestive heart failure (greater than New York Heart Association class II), severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia, poorly controlled diabetes, severe chronic pulmonary disease, coronary angioplasty, or myocardial infarction within 6 months prior to screening, or uncontrolled atrial or ventricular cardiac arrhythmias.\n* Congenital long QT syndrome or a corrected QT interval (QTc) ≥480 ms at screening (unless secondary to pacemaker or bundle branch block).\n* Active second primary malignancy within 3 years of Screening other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, or ductal or lobular carcinoma in situ of the breast",{"count":319,"type":22},80,[25],"This study will investigate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 in participants with advanced or metastatic Microsatellite Stable (MSS)\u002FMicrosatellite Instability Low (MSI-L) Colorectal Cancer",[323,324,325,326,327,32,328],"Colorectal Cancer","Colorectal Cancer (CRC)","Colorectal (Colon or Rectal) Cancer","CRC","Metastatic Colon Cancer","Advanced Colorectal Cancer",[330,194,331,332,333,334,335,336,337],"Oncology","Phase 1","First-in-Human","Dose Escalation","Open-Label","T-Cell Engager","TCE","CartographyBio","2026-07-27",{"date":340,"type":44},"2026-07-28",{"date":342,"type":44},"2026-01-15",{"date":344,"type":22},"2029-10",{"name":346,"class":174},"Cartography Biosciences",10,{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":119,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":357,"conditions":358,"keywords":363,"overallStatus":244,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":373,"locationsCount":52},"100649344","analysis-of-breath-volatile-organic-compounds-using-mass-spectrometry-100649344","NCT07732686","Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry","Breath Volatile Organic Compounds (VOC) Analysis Using Proton Transfer Reaction Mass Spectrometry (PTR-MS)","Inclusion Criteria:\n\n* Age ≥ 18 at the time of consent. Male and female patients to be tested.\n* Capable of understanding written and\u002For spoken English language.\n* Able to provide informed consent.\n* Cancer of any type.\n* Newly diagnosed cancer and untreated or established diagnosis of cancer. For established cancer patients, no active anti-cancer treatment for more than one month (reasons for no treatment are such as relapse, progression of cancer, refractory, or intolerance to treatment etc.)\n\nExclusion Criteria:\n\n* Under the age of 18.\n* Anticipated inability to complete breath sampling procedure.\n* Unable to provide informed consent.\n* Pregnant women\n* Active respiratory infection symptoms\n* Recent use of antibiotics\n* Difficulty in performing coached exhalation\n* Individuals who are unable to follow the instructions\n* Cancer patients who are on active treatment for cancer or have received cancer treatment within one month",{"count":356,"type":22},2000,"The purpose of this clinical trial is to evaluate whether volatile organic compound (VOC) signatures detected in the breath of patients with cancer can serve as a potential screening tool for the early detection of cancer.",[359,360,125,274,98,273,32,361,362],"Pancreas Cancer","Hepatocellular Carcinoma","Bladder Cancer","Other Cancer",[364,365,366],"VOC","PTR-MS","ML","2026-07-23",{"date":369,"type":44},"2026-07-29",{"date":371,"type":22},"2026-10",{"date":344,"type":22},{"name":374,"class":84},"University of Oklahoma",{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":383,"conditions":384,"keywords":393,"overallStatus":244,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":4},"100648184","coloflow-laser-speckle-contrast-imaging-versus-near-infrared-fluorescence-imaging-with-indocyanine-green-100648184","NCT07720505","COLOFLOW: Laser Speckle Contrast Imaging Versus Near-infrared Fluorescence Imaging With Indocyanine Green","COLOFLOW","Inclusion Criteria:\n\n* Adults ≥18 years.\n* Undergoing elective colon resection with primary anastomosis.\n* Able to provide consent for postoperative analysis of intraoperative imaging\n\nExclusion Criteria:\n\n* Palliative surgery.\n* Factors that severely limit intraoperative visualization (per investigator judgement).\n\nConditions interfering with perfusion assessment (e.g., severe peripheral vascular compromise).",{"count":149,"type":22},"COLOFLOW is a prospective observational study investigating whether Laser Speckle Contrast Imaging (LSCI), a dye-free and objective perfusion imaging technique, corresponds with the currently used subjective assessment of indocyanine green (ICG) fluorescence during colorectal surgery. In approximately 30 patients undergoing elective colon or rectal resection with primary anastomosis, both imaging modalities will be performed intraoperatively. The surgeons will base their clinical decisions solely on standard ICG fluorescence imaging, while LSCI measurements are collected for research purposes and do not influence treatment. Postoperatively, quantitative ICG parameters will be analysed and compared with LSCI perfusion maps to determine whether objective ICG analysis improves agreement with LSCI over subjective interpretation alone. In addition, the study will evaluate the feasibility of using the PerfusiX-IGS LSCI system during open colorectal surgery and describe postoperative outcomes, including anastomotic leakage. The ultimate goal is to contribute to more objective and standardized perfusion assessment during colorectal surgery",[385,32,386,387,388,389,390,391,392],"Leakage, Anastomotic","Colon Anastomosis","Colon and Rectal Cancer","Colon Benign Tumor","Colon and Rectal Diseases","Laser Speckle Contrast Imaging","Indocyanine Green (ICG)","Near-Infrared Spectroscopy",[394,395,396,397,398,399],"colon","anastomosis","laser speckle contrast imaging","indocyanine green","ICG","Near-infrared","2026-07-17",{"date":402,"type":44},"2026-07-22",{"date":404,"type":22},"2026-08-01",{"date":406,"type":22},"2027-09-30",{"name":408,"class":84},"Leiden University Medical Center",{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":12,"sex":17,"minAge":415,"maxAge":416,"enrollmentInfo":417,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":419,"conditions":420,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":52},"100587332","chronic-loose-stools-following-right-sided-hemicolectomy-for-colon-cancer-and-the-association-with-bile-acid-malabsorption-and-small-intestinal-bacterial-overgrowth-using-a-novel-sampling-device-100587332","NCT06927011","Chronic Loose Stools Following Right-sided Hemicolectomy for Colon Cancer and the Association With Bile Acid Malabsorption and Small Intestinal Bacterial Overgrowth Using a Novel Sampling Device","Inclusion Criteria:\n\n* Both men and women of all races and ethnic groups are eligible for this trial who meet the above criteria.\n\nExclusion Criteria:\n\n* Children will not be enrolled in this study.\n* Pregnant women will not be enrolled in this study.\n* Cognitively impaired subjects will not be enrolled in this study.","20 Years","85 Years",{"count":418,"type":22},20,"The goal of this clinical research study is to learn about gastrointestinal symptoms in participants who have undergone SC or RC and their impact on the quality of life of these participants.",[32],"2026-07-14",{"date":423,"type":44},"2026-07-16",{"date":425,"type":44},"2025-10-31",{"date":427,"type":22},"2028-12-30",{"name":429,"class":84},"M.D. Anderson Cancer Center",{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":436,"targetDuration":4,"studyType":23,"phases":438,"briefSummary":439,"conditions":440,"keywords":443,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":52},"100542267","washington-university-participant-engagement-and-cancer-genomic-sequencing-center-wu-pe-cgs-100542267","NCT06340646","Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)","Eligibility Criteria:\n\n* Patients with cholangiocarcinoma, multiple myeloma, or early onset colon or rectal cancer.\n\n  * If diagnosed with multiple myeloma, must be African-American.\n  * If diagnosed with colon or rectal cancer, must be African-American AND must be no older than 65 years old at the time of diagnosis.\n  * At least 18 years old\n  * Able to understand and willing to sign an IRB-approved written informed consent document",{"count":437,"type":22},990,[65],"The overall goal of the WU-PE-CGS is to build a rigorous, scientific evidence base for approaches that direct engagement of cancer patients and post-treatment cancer survivors as participants in cancer research, and to investigate the impact of directly engaging participants in decisions regarding returning of genomic results on participants' health and satisfaction. Participants in this study will be presented with the choice of types of genomic results to receive, and the Engagement Optimization Unit (EOU) will investigate the impact of this intervention on participant knowledge, expectations of benefit, personal utility, and decisional conflict.",[441,442,32,33],"Cholangiocarcinoma","Multiple Myeloma",[444,445,441,442,446,447],"Participant engagement","Genetic testing","Colorectal cancer","Underrepresented populations","2026-07-11",{"date":421,"type":44},{"date":451,"type":44},"2022-10-18",{"date":453,"type":22},"2027-01-31",{"name":455,"class":84},"Washington University School of Medicine",{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":23,"phases":464,"briefSummary":465,"conditions":466,"keywords":467,"overallStatus":244,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":52},"100645627","ctdna-and-tep-levels-in-colon-cancer-100645627","NCT07701408","ctDNA and TEP Levels in Colon Cancer","Determination of ctDNA and TEP Levels in Patients With Colon Cancer Receiving Neoadjuvant Systemic Therapy","Inclusion Criteria:\n\n* Age 18 years or older at the time of enrollment.\n* Histologically confirmed adenocarcinoma of the colon.\n* Stage III colon cancer, defined according to the applicable TNM classification based on clinical and imaging assessment.\n* Confirmed mismatch repair (MMR) status, determined by immunohistochemistry and\u002For molecular methods.\n* Planned neoadjuvant systemic therapy according to MMR status, followed by surgical resection with curative intent.\n* ECOG performance status 0-2.\n* Ability to understand the study and provide written informed consent.\n\nExclusion Criteria:\n\n* Stage I, II, or IV colon cancer.\n* Concurrent active malignant disease, except adequately treated non-melanoma skin cancer or carcinoma in situ.\n* Severe comorbidities or medical conditions that prevent or substantially limit neoadjuvant systemic therapy or surgical resection.\n* Known autoimmune disease requiring active immunosuppressive treatment in patients with dMMR tumors.\n* Pregnancy or breastfeeding.\n* Inability or unwillingness to provide written informed consent.",{"count":319,"type":22},[65],"This interventional cohort study will evaluate circulating tumor DNA (ctDNA) and tumor-educated platelets (TEP) as blood-based biomarkers in adults with stage III colon cancer who are planned to receive neoadjuvant systemic therapy followed by surgical resection.\n\nTreatment will be given according to routine clinical practice and will depend on the biological characteristics of the tumor, including mismatch repair status. Participants will provide additional blood samples at predefined time points before, during, and after treatment and surgery. These samples will be used to analyze ctDNA and TEP and to assess whether changes in these biomarkers are associated with radiological response, pathological response, and disease-free outcomes.\n\nApproximately 80 participants will be enrolled at the Institute of Oncology Ljubljana. Participants will not receive experimental drugs as part of this study.",[32],[468,469,470,471,472],"ctDNA","Circulating Tumor DNA","Tumor-Educated Platelets","TEP","Neoadjuvant Systemic Therapy","2026-07-08",{"date":421,"type":44},{"date":476,"type":22},"2026-08",{"date":478,"type":22},"2028-06",{"name":480,"class":84},"Institute of Oncology Ljubljana",{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":487,"eligibilityCriteria":488,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":489,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":491,"conditions":492,"keywords":493,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":52},"100612603","an-exosomal-microrna-signature-for-preoperative-staging-in-colon-cancer-100612603","NCT07255729","An Exosomal microRNA Signature for Preoperative Staging in Colon Cancer","Machine Learning-Based Exosomal microRNA Signature for Preoperative Staging and Chemotherapy Eligibility in Colon Cancer","EXPOSE","Inclusion Criteria:\n\n* Pathologically confirmed colon cancer (Stage I-IV, UICC TNM 8th edition)\n* Underwent curative-intent resection (with or without perioperative therapy)\n* Preoperative plasma (or serum) samples available\n* Clinical and prognostic data available\n\nExclusion Criteria:\n\n* No written informed consent\n* Missing preoperative blood samples\n* Missing survival\u002Frecurrence data\n* Duplicate cases\n* Non-adenocarcinoma histology",{"count":490,"type":22},400,"Recent studies have highlighted the potential benefits of neoadjuvant chemotherapy (NAC) in colon cancer; however, its indication is generally limited to cases corresponding to pathological stage IIB or higher. Accurately identifying such high-risk cases before surgery remains challenging using conventional clinical diagnostics alone. Therefore, we hypothesized that integrating molecular biomarkers with preoperative clinical assessment could provide a more precise and sensitive evaluation of tumor aggressiveness. In this context, we focused on exosomal microRNAs, which are actively secreted from tumor cells and remain stable in circulation, and aimed to develop a machine learning-based biomarker panel. To achieve this, we initiated a multicenter study utilizing preoperative plasma samples to establish a reliable biomarker model for risk stratification and treatment decision-making in colon cancer.",[32],[494,495,496,497,498,499],"CC","NAC","miRNA","Exosomal miRNA","Staging","liquid biopsy","2026-07-06",{"date":502,"type":44},"2026-07-07",{"date":504,"type":44},"2025-01-15",{"date":506,"type":22},"2028-06-18",{"name":508,"class":84},"City of Hope Medical Center",{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":119,"sex":17,"minAge":516,"maxAge":4,"enrollmentInfo":517,"targetDuration":519,"studyType":95,"phases":4,"briefSummary":520,"conditions":521,"keywords":522,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":538},"100607264","exopert-emerald-clinical-study-100607264","NCT07186296","EXoPERT EMERALD Clinical Study","EXoPERT EMERALD: Early Multi-cancer Study of EV's Ramen-AL Linked Diagnosis Clinical Study Protocol","Inclusion Criteria:\n\n* Subject aged 45 years or older with a biopsy-proven or clinically suspected primary lung, breast, colorectal, pancreatic, or ovarian cancer, based on objective findings such as radiological, serological, endoscopic, or cytological findings, whose blood was collected prior to any systemic or definitive therapy for the cancer.\n* Subjects who are willing and able to provide written informed consent.\n* Subjects who are willing and able to comply with the study requirements.\n\nExclusion Criteria:\n\n* Any history of cancer diagnosed and treated within 5 years prior to the date of consent.\n* Subjects with a history of previous cancer treatment via surgical resection, hormonal cancer treatment, chemotherapy, radiotherapy within the past 6 months for recent cancer diagnosis.\n* Subjects who have any history of an allogeneic bone marrow, stem cell transplant, or solid organ transplant.\n* Subjects who are pregnant or breastfeeding women.\n* Subjects who have consented and have undergone treatment in any other cancer related clinical trials withinthe past 6 months.\n* Subjects who are currently in active treatment for drug abuse.\n* Subjects who have received any treatment related to lung, breast, colorectal, pancreatic, or ovarian nodules, such as hormones prior to entering the study.\n* Unsuitable sample for testing due to contamination, hemolysis, etc.","45 Years",{"count":518,"type":22},1400,"1 Day","The purpose of this study is to establish a multi-center clinical repository of blood samples to support the development and evaluation of an artificial intelligence-based in vitro diagnostic software. The software analyzes surface-enhanced Raman spectroscopy (SERS) profiles of extracellular vesicles (EVs) extracted from human plasma for the early detection of multiple cancers, including lung, ovarian, breast, pancreatic, and colorectal cancers.",[98,32,29,274,125],[523,524,525,526,527,528],"Early-stage","In vitro Diagnostic Test","Artificial intelligence","extracellular vesicles","multi cancer diagnosis","cancer","2026-06-28",{"date":531,"type":44},"2026-07-01",{"date":533,"type":44},"2025-05-09",{"date":535,"type":22},"2026-08-31",{"name":537,"class":174},"EXoPERT",9,{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":543,"acronym":544,"eligibilityCriteria":545,"healthyVolunteers":119,"sex":17,"minAge":212,"maxAge":546,"enrollmentInfo":547,"targetDuration":549,"studyType":95,"phases":4,"briefSummary":550,"conditions":551,"keywords":585,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":596,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":602,"locationsCount":604},"100210159","integrated-cancer-repository-for-cancer-research-100210159","NCT02012699","Integrated Cancer Repository for Cancer Research","iCaRe2","Inclusion Criteria\n\n* Diagnosis\u002Fhistory of cancer\n* Risk for developing cancer or suspicious clinical findings\n* No history of cancer (normal control registry)\n* Able to provide informed consent\n* 19 years of age or older\n* English or Spanish speaking individuals\n\nExclusion Criteria\n\n* Unable to provide informed consent because of cognitive impairment\n* Non-English or non-Spanish speaking individuals","110 Years",{"count":548,"type":22},999999,"80 Years","The iCaRe2 is a multi-institutional resource created and maintained by the Fred \\& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.",[29,552,125,270,553,32,33,554,266,555,556,557,30,126,558,559,560,561,361,272,562,124,563,564,565,566,567,568,569,570,571,572,573,574,575,576,577,158,98,578,579,275,580,442,274,269,581,582,583,584],"Thyroid Cancer","Thymus Cancer","Gastrointestinal Stromal Tumors","Bile Duct Cancer","Duodenal Cancer","Gallbladder Cancer","Small Intestine Cancer","Peritoneal Surface Malignancies","Familial Adenomatous Polyposis","Lynch Syndrome","Penile Cancer","Testicular Cancer","Ureter Cancer","Urethral Cancer","Hypopharyngeal Cancer","Laryngeal Cancer","Lip Cancer","Oral Cavity Cancer","Nasopharyngeal Cancer","Oropharyngeal Cancer","Paranasal Sinus Cancer","Nasal Cavity Cancer","Salivary Gland Cancer","Skin Cancer","Central Nervous System Tumor","Central Nervous System Cancer","Leukemia","Melanoma","Unknown Primary Tumor","Vaginal Cancer","Neuroendocrine Tumors","Plasma Cell Dyscrasia","Healthy Control",[29,552,586,587,588,589,590,591,592,593,98,594,583,584],"Esophageal cancer","Thymus cancer","Pancreatic tumor","Esophageal tumor","Thymus tumor","Thyroid Tumor","Thyroid Nodule","Lung Tumor","Neuroendocrine tumor","2026-06-25",{"date":597,"type":44},"2026-06-29",{"date":599,"type":44},"2013-11-01",{"date":601,"type":22},"2099-12",{"name":603,"class":84},"University of Nebraska",42,{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":611,"eligibilityCriteria":612,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":613,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":614,"conditions":615,"keywords":4,"overallStatus":244,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":618,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":623,"locationsCount":4},"100644786","improving-prognostication-in-colon-cancer-100644786","NCT07673393","Improving Prognostication in Colon Cancer","Improving Prognostication of Localised Colon Cancer by Combining Liquid Biopsy and Histology: a Multicentric, Prospective Study","MARBLE","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.\n2. Male and female participants, at least 18 years of age at the time of signing the Informed Consent Form (ICF).\n3. Newly diagnosed primary colon tumor clinically and\u002For histologically consistent with localized colon adenocarcinoma and planned for curative-intent surgical resection.\n4. Clinical stage compatible with non-metastatic disease at time of screening and considered eligible for standard curative-intent management according to investigator assessment.\n5. WHO (ECOG) performance status ≤ 3 at baseline.\n\nExclusion Criteria:\n\n1. Participant has been diagnosed with metastatic disease (Stage IV)\n2. Participant has been diagnosed with rectal cancer\n3. Participant has been diagnosed with synchronous primary colon tumors (i.e., presence of two or more primary colon tumors detected simultaneously at diagnosis)\n4. Participant has received prior systemic therapy (chemotherapy, targeted therapy, immunotherapy, or radiotherapy) for colon cancer\n5. Participation in an interventional Study with an investigational medicinal product (IMP) or device within 30 days prior to inclusion.\n6. Participant had prior history of colon cancer requiring systemic treatment or major colorectal oncologic surgery.\n7. Any severe, uncontrolled, or life-threatening medical condition that, in the opinion of the investigator, could interfere with study participation, interpretation of study assessments, or pose excessive risk to the participant (e.g. severe cardiac, hepatic, renal, or uncontrolled infectious disease).",{"count":490,"type":22},"The goal of this study is to test better ways to predict if cancer will return after surgery in adults (18+) who have been diagnosed with stage II or III colon cancer.\n\nThe main questions it aims to answer are:\n\n* Can computer programs (Artificial Intelligence) and special blood tests give more accurate information about the risk of cancer returning than the methods doctors use today?\n* Does combining these new tests help doctors better understand which patients really need chemotherapy and which do not?\n\nResearchers will compare the new computer and blood tests to the standard hospital methods used now to see if the new way is more accurate in predicting the cancer's behavior\n\nParticipants will:\n\n* Sign a form saying they agree to take part in the study\n* Have their standard surgery to remove the tumor\n* Give a few extra teaspoons of blood during their regular, scheduled hospital visits\n* Allow researchers to scan and study a small piece of the tumor that was already removed during surgery\n* Continue with their normal hospital check-ups for up to five years so researchers can track their health",[32,616],"Colon Adenocarcinoma","2026-06-22",{"date":597,"type":44},{"date":620,"type":22},"2026-09",{"date":622,"type":22},"2033-09",{"name":624,"class":84},"Universitaire Ziekenhuizen KU Leuven",{"id":626,"slug":627,"hasResults":12,"nctId":628,"briefTitle":629,"officialTitle":630,"acronym":631,"eligibilityCriteria":632,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":633,"enrollmentInfo":634,"targetDuration":4,"studyType":23,"phases":636,"briefSummary":637,"conditions":638,"keywords":640,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":645,"startDateStruct":646,"completionDateStruct":648,"leadSponsor":650,"locationsCount":652},"100643932","phase-3-evaluation-of-nuvastatictm-in-reducing-cancer-related-fatigue-in-stage-iv-colon-cancer-patients-undergoing-first-line-chemotherapy-100643932","NCT07669519","Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Stage IV Colon Cancer Patients Undergoing First-Line Chemotherapy","Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NuvastaticTM in Reducing Cancer-Related Fatigue in Stage IV Colon Cancer Patients Undergoing First-Line Chemotherapy","NuvastaticTM","Inclusion Criteria:\n\n1. Male and female Patients who are ≥18 and ≤65 years of age, who are willing to voluntarily provide consent for participation in the study.\n2. Patients with colon cancer planned or scheduled to receive standard chemotherapy treatment for at least 3 cycles respectively.\n3. Patients must have a confirmed diagnosis of colon cancer as per standard guideline.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at Screening.\n5. The patient has stable haemoglobin (≥ 9 g\u002FdL) throughout the screening.\n6. Life expectancy ≥ 6 months, as per Investigator's judgment\n7. Patients with co-morbidities or medical conditions including Type 2 DM, hypertension and are deemed stable by the investigator can be included in the study\n8. At screening patients with stable fatigue, has a newly developed fatigue OR worsening of fatigue scoring as assessed by BFI should be included.\n9. Starting first-line chemo\n\nExclusion Criteria:\n\n1. Patients who have any untreated reversible medical condition which may cause fatigue (e.g. metabolic disturbance, infection, endocrine abnormalities) as per the Investigator's clinical judgment.\n2. Patients who have stage IV Disease\n3. Patients who have received concurrent stimulant medication (e.g. dextroamphetamine or methylphenidate) during the screening period or any medication which may interfere with study drug.\n4. Prior metastatic chemo, targeted\u002Fimmunotherapy, severe comorbidities\n5. Female patients who are pregnant or breast-feeding.\n6. Patients with known hepatitis C virus, hepatitis B virus, HIV infection.\n7. Patients who have nausea and vomiting or any gastrointestinal disorder that is severe enough to interfere with study drug absorption in the opinion of the Investigator.\n8. Patients with uncontrolled pain, who in the opinion of the Investigator are not eligible for the study. '\n9. Patients with planned therapy or treatment with another investigational agent.\n10. Previous exposure to any investigational agent within 4 weeks prior to screening, or planned administration of an Investigational agent, other than as specified by this protocol, during the study period.","65 Years",{"count":635,"type":22},180,[216],"The goal of this clinical trial is to evaluate whether Nuvastatic can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy.\n\nThe main questions it aims to answer are:\n\nDoes Nuvastatic significantly reduce cancer-related fatigue compared to placebo? Is Nuvastatic safe and well tolerated in this patient population?\n\nResearchers will compare Nuvastatic vs placebo to see if Nuvastatic improves fatigue scores and maintains an acceptable safety profile.\n\nParticipants will:\n\nReceive Nuvastatic or placebo sachets (3 times per day) for 3 cycles of 20 days each (total \\~60 treatment days).\n\nContinue their standard first-line chemotherapy regimen. Provide blood samples for biomarkers (CEA, CA-125) at Screening and End of Treatment.\n\nComplete patient diaries and fatigue assessments as per protocol.",[639,32],"Fatigue",[32,641,642,643,644],"Cancer-Related Fatigue","Nuvastatic","Randomized Double-Blind Placebo-Controlled Trial","First-Line Chemotherapy",{"date":595,"type":44},{"date":647,"type":44},"2025-08-18",{"date":649,"type":22},"2027-03-31",{"name":651,"class":174},"Natureceuticals Sdn Bhd",6,{"id":654,"slug":655,"hasResults":12,"nctId":656,"briefTitle":657,"officialTitle":657,"acronym":631,"eligibilityCriteria":658,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":633,"enrollmentInfo":659,"targetDuration":4,"studyType":23,"phases":661,"briefSummary":662,"conditions":663,"keywords":665,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":668,"startDateStruct":669,"completionDateStruct":671,"leadSponsor":673,"locationsCount":652},"100643923","phase-3-a-randomized-double-blind-placebo-controlled-parallel-group-comparative-phase-iii-study-to-evaluate-the-efficacy-and-safety-of-nuvastatic-300mg-capsule-in-reducing-cancer-tumor-in-patients-with-metastatic-colorectal-cancer-receiving-standard-chemotherapy-100643923","NCT07669454","A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.","Inclusion Criteria:\n\n* Male and female patients who are ≥18 and ≤65 years of age, who are willing to voluntarily provide consent for participation in the study.\n* Patients with metastatic colorectal cancer planned or scheduled to receive standard chemotherapy treatment for at least 6 cycles respectively.\n* Patients must have a confirmed diagnosis of metastatic colorectal cancer as per standard guidelines.\n* Patients must have at least one tumor lesion with ≥ 1cm in one dimension that is radiographically apparent on computed tomography (CT) or magnetic resonance imaging (MRI).\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at Screening.\n* Life expectancy ≥ 6 months, as per investigator's judgment.\n* The patient has stable hemoglobin (≥ 9 g\u002FdL)throughout the screening.\n* Patients with co-morbidities or medical conditions including Type 2 diabetes mellitus (DM), hypertension who are deemed stable by the investigator can be included in the study.\n\nExclusion Criteria:\n\n* Patients who have any untreated reversible medical condition which may cause fatigue (e.g. metabolic disturbance, infection, endocrine abnormalities) as per the investigator's clinical judgment.\n* Patients with an inability to understand local language(s) for scales used for evaluations, i.e., EORTC QLQ-C30, BFI, SF-36 and VAS-F.\n* Patients who have received concurrent stimulant medication (e.g. dextroamphetamine or methylphenidate) during the screening period or any medication which may interfere with the study drug.\n* Patients with any delay in chemotherapy treatment such that the screening period extends beyond 21 days.\n* Patients with known central nervous system (CNS) are involved by metastatic cancer.\n* Patients with any serious, uncontrolled, non-malignant medical or psychiatric disorder, or any other medical condition which in the opinion of the investigator may affect the patient's safety or study participation and conduct.\n* Female patients who are pregnant or breastfeeding.\n* Patients with known hepatitis C virus, hepatitis B virus, HIV infection.\n* Patients who have nausea and vomiting or any gastrointestinal disorder that is severe enough to interfere with study drug absorption in the opinion of the investigator.\n* Patients with uncontrolled pain who, in the opinion of the investigator, are not eligible for the study.\n* Patients with known hypersensitivity or intolerance of rosmarinic acid, caffeic acid, and other related phenolic compounds as well as excipients in the Nuvastatic® 300 mg or placebo treatment.\n* Patients with planned therapy or treatment with another investigational agent.\n* Previous exposure to any investigational agent within 4 weeks prior to screening, or planned administration of an Investigational agent, other than as specified by this protocol, during the study period.",{"count":660,"type":22},250,[216],"The goal of this clinical trial is to evaluate whether Nuvastatic 300 capsule can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy.\n\nThe main questions it aims to answer are:\n\nDoes Nuvastatic 300 capsule significantly reduce cancer-related fatigue compared to placebo? Is Nuvastatic 300 capsule safe and well tolerated in this patient population?\n\nResearchers will compare Nuvastatic 300 capsule vs placebo to see if Nuvastatic 300 capsule improves fatigue scores and maintains an acceptable safety profile.\n\nParticipants will:\n\nReceive Nuvastatic 300 capsule or placebo capsules (3 times per day) for 6 cycles of 20 days each (total \\~120 treatment days).\n\nContinue their standard first-line chemotherapy regimen. Provide blood samples assessment at Screening and End of Treatment. Complete patient diaries and fatigue assessments as per protocol.",[664,32],"Fatigue Related to Cancer Treatment",[642,32,666,667,644],"Cancer related fatigue","Randomized double blind placebo controlled trial",{"date":595,"type":44},{"date":670,"type":44},"2025-10-01",{"date":672,"type":22},"2026-11-30",{"name":651,"class":174},{"id":675,"slug":676,"hasResults":12,"nctId":677,"briefTitle":678,"officialTitle":679,"acronym":4,"eligibilityCriteria":680,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":681,"targetDuration":4,"studyType":23,"phases":683,"briefSummary":684,"conditions":685,"keywords":689,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":697,"startDateStruct":699,"completionDateStruct":701,"leadSponsor":703,"locationsCount":705},"100414594","phase-1-a-trial-of-rsc-1255-for-treatment-of-patients-with-advanced-malignancies-100414594","NCT04678648","A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies","A Phase Ia\u002FIb, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of RSC-1255 Alone or in Combination With Hydroxychloroquine in Patients With Advanced Solid Tumor Malignancies","Inclusion Criteria (Key Factors):\n\n1. Has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following:\n\n   * Participant is intolerant of existing therapy(ies) known to provide clinical benefit for their condition\n   * Malignancy is refractory to existing therapy(ies) known to potentially provide clinical benefit\n   * Malignancy has progressed on standard therapy\n2. Has evaluable or measurable tumor(s) in dose-escalation by standard radiological and\u002For laboratory assessments as applicable to their malignancy.\n3. Has adequate performance status (PS): Eastern Co-operative Oncology Group (ECOG).\n4. Is age ≥ 18 years.\n5. Has either tissue agnostic tumors and documented RAS mutations or with glioblastoma with or without mutation in RAS\n\nExclusion Criteria (Key Factors):\n\n1. Participants receiving cancer therapy at the time of enrollment.\n2. Any clinically significant disease or condition affecting a major organ system.\n3. Significant cardiovascular disease or electrocardiogram (ECG) abnormalities.\n4. Known Gilbert's disease.\n5. Has had a previous (within 2 years) or has a current malignancy other than the target cancer.\n6. Intermittent hypokalemia\n7. Grade 1 or higher nausea, vomiting, diarrhea at baseline due to underlying disease",{"count":682,"type":22},134,[25],"RSC-101 is a Phase 1a\u002F1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.",[686,687,125,32,688,29],"Advanced Malignant Solid Neoplasm","RAS Mutation","Glioblastoma",[132,131,690,691,692,693,688,694,695,696],"Refractory","RAS mutation","Lung","Colon","RSC-1255","Progression","Pancreatic",{"date":698,"type":44},"2026-06-23",{"date":700,"type":44},"2021-03-03",{"date":702,"type":22},"2027-01-30",{"name":704,"class":174},"RasCal Therapeutics, Inc.",3,{"id":707,"slug":708,"hasResults":12,"nctId":709,"briefTitle":710,"officialTitle":710,"acronym":4,"eligibilityCriteria":711,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":712,"targetDuration":4,"studyType":23,"phases":713,"briefSummary":714,"conditions":715,"keywords":717,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":725,"lastUpdatePostDateStruct":726,"startDateStruct":727,"completionDateStruct":729,"leadSponsor":731,"locationsCount":733},"100622718","mainstreaming-genetics-evaluation-of-a-digital-application-to-scale-and-spread-oncologist-initiated-genetic-testing-100622718","NCT07387263","Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing","Inclusion Criteria:\n\n* Receiving germline testing related to primary cancer condition initiated by oncologist\n* 18 years old or older.\n* Speak and read English\n\nExclusion Criteria:\n\n* Receiving cancer genetic testing via a referral to a genetics clinic\n* Do not speak or read English\n* Under 18 years of age\n* Determined to have diminished, marginal and or fluctuating decisional capacity\n* Lack access to internet or an electronic device",{"count":635,"type":22},[65],"Genetic testing can alter therapy and surgical management for cancer patients and is therefore indicated as a first-line test for many newly diagnosed patients, including breast, ovarian, pancreatic, prostate and colon\u002FGI patients. To reduce pressure on already constrained genetics clinics across Canada, some cancer centres are 'mainstreaming' genetic testing - whereby genetic testing is initiated and mediated by oncologists without traditional pre-test genetic counseling (GC) often using some form of paper-based patient pamphlets or videos. There is no standard, evidence-based approach to mainstreaming, leading to significant practice variation, a lack of coordinated care and ultimately, negative psychological impacts on patients. Digital solutions can address these gaps by providing a standardized, coordinated and patient-centered approach to deliver cancer genetic education. However, digital solutions for providing cancer genetics services are uncommon and clinical-effectiveness and service delivery outcomes have not been well-assessed. This study will test a digital mainstreaming platform called the Genetics Adviser for Mainstream care to assess its effectiveness in improving psychological outcomes and patient-centred care for mainstream cancer patients compared to standard of care.",[131,98,124,32,716,274,29],"GI Cancers",[718,719,720,721,722,131,445,723,724],"Cancer Genetic Testing","Randomized Controlled Trial","Digital Tool","Mainstreaming","Genetic counseling","Service Delivery","Alternative service delivery model","2026-06-19",{"date":169,"type":44},{"date":728,"type":44},"2026-04-30",{"date":730,"type":22},"2027-03",{"name":732,"class":84},"Unity Health Toronto",2,{"id":735,"slug":736,"hasResults":12,"nctId":737,"briefTitle":738,"officialTitle":738,"acronym":4,"eligibilityCriteria":739,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":740,"enrollmentInfo":741,"targetDuration":4,"studyType":23,"phases":742,"briefSummary":743,"conditions":744,"keywords":746,"overallStatus":244,"whyStopped":4,"lastUpdateSubmitDate":751,"lastUpdatePostDateStruct":752,"startDateStruct":754,"completionDateStruct":755,"leadSponsor":756,"locationsCount":52},"100642750","phase-2-ql1706-combined-with-standard-therapy-for-conversion-therapy-of-synchronous-liver-metastases-from-colon-cancer-a-multicenter-single-arm-exploratory-study-100642750","NCT07649473","QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study","Inclusion Criteria:\n\n* Aged 18 to 70 years, male or female.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n* Histologically or cytologically confirmed colon adenocarcinoma, with pathologically or radiographically verified liver-only metastases.\n* Microsatellite stable (MSS) \u002F proficient mismatch repair (pMMR) confirmed by immunohistochemistry (IHC) or polymerase chain reaction (PCR).\n* No prior local or systemic anti-tumor therapy for colon cancer liver metastases, including but not limited to targeted therapy, immunotherapy, systemic or hepatic arterial infusion chemotherapy, radiotherapy and surgery.\n* Inclusion criteria for liver metastases: ① More than 5 liver metastatic lesions, with at least one lesion measuring less than 3 cm in diameter; ② Child-Pugh Class A; ③ Future Liver Remnant (FLR) \u002F Standard Liver Volume (SLV) \\> 30% for patients without liver cirrhosis, or \\> 40% for patients with liver cirrhosis; ④ Exclude lesions involving complicated surgical sites, such as biliary tract reconstruction, vascular reconstruction, invasion of hepatic hilum, portal vein or inferior vena cava.\n* At least one radiographically measurable lesion per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).\n* Expected survival of no less than 12 weeks.\n* Laboratory test results meet the following criteria within 7 days prior to the first study drug administration (No blood products, hematopoietic growth factors, albumin or other corrective medications deemed necessary by the investigator shall be administered within 14 days before testing):\n\n  1. Biochemistry: Alkaline phosphatase (ALP), alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 3 × upper limit of normal (ULN), or ≤ 5 × ULN in patients with liver metastases; Total bilirubin (TBIL) ≤ 1.5 × ULN, or ≤ 2 × ULN in patients with liver metastases; Serum creatinine ≤ 1.5 × ULN, or creatinine clearance \\> 50 mL\u002Fmin (calculated via Cockcroft-Gault formula).\n  2. Hematology: Hemoglobin (Hb) ≥ 9.0 g\u002FdL; No red blood cell transfusion within 1 week (including the test day) before baseline Hb test; Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL; Platelet count ≥ 100 × 10⁹\u002FL; No platelet transfusion within 1 week (including the test day) before baseline platelet test.\n  3. Coagulation function: International Normalized Ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN. For subjects receiving prophylactic anticoagulation without active bleeding (no bleeding within the past 14 days), INR ≤ 2 × ULN and APTT within normal range.\n  4. Urinalysis: Urinary protein ≤ 30 mg\u002FdL (1+) by dipstick or routine urinalysis. If urine protein ≥ 2+, 24-hour urinary protein quantification shall be less than 1 g\u002F24h.\n* No contraindications to radiotherapy, chemotherapy or immunotherapy.\n* For female subjects of childbearing potential: serum pregnancy test must be negative within 7 days prior to enrollment. They must agree to use effective contraception throughout the study and for 5 months after the last study drug administration. Male subjects with partners of childbearing potential must also use effective contraception during the study and for 5 months after the last dose. Lactating women are excluded.\n* Subjects must be fully informed of the study prior to enrollment, voluntarily sign the written informed consent form, and be willing and able to comply with all scheduled visits, treatment plans, laboratory tests and other study procedures.\n\nExclusion Criteria:\n\n* Confirmed non-adenocarcinoma pathological types via histopathology or cytopathology, including squamous cell carcinoma, undifferentiated carcinoma, neuroendocrine carcinoma, etc. For mixed pathological types, eligibility is determined by the predominant component; patients are eligible only if a pathologist confirms the adenocarcinoma component accounts for more than 70%. Patients with primary appendiceal tumors are excluded.\n* Presence of distant metastases at sites other than the liver.\n* Prior systemic treatment with anti-PD-1, anti-PD-L1, anti-CTLA-4 antibodies or other immunotherapeutic agents, or the CAPOX regimen. Prior radiotherapy for liver metastases, or prior radiation exposure to normal liver tissue adjacent to the planned irradiation field.\n* History of other malignant tumors within 5 years prior to enrollment, except cured carcinoma in situ of the cervix, basal cell or squamous cell skin cancer, radically treated localized prostate cancer, and radically treated ductal carcinoma in situ.\n* Active autoimmune diseases requiring systemic treatment (with immunomodulators, corticosteroids or immunosuppressants) within the past 2 years. Replacement therapies such as thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency are permitted and not regarded as systemic immunosuppressive treatment.\n* Immunodeficiency, or receipt of long-term systemic corticosteroids (prednisone equivalent \\> 10 mg per day) or other immunosuppressants within 7 days before enrollment or anticipated during study treatment.\n* Uncontrolled pleural effusion, pericardial effusion, or moderate to severe ascites.\n* Tumor-related complications such as bleeding, perforation or intra-abdominal infection within 3 months prior to enrollment.\n* Clinically significant bleeding symptoms or high bleeding risk within 3 months prior to enrollment, including gastrointestinal hemorrhage, gastroesophageal varices, bleeding gastric ulcer, hematochezia, hematemesis or hemoptysis. Presence of gastrointestinal disorders including active peptic ulcer, ulcerative colitis, gastrointestinal perforation, unhealed gastrointestinal fistula, malabsorption syndrome or uncontrolled inflammatory bowel disease.\n* Thrombotic or thromboembolic events including cerebrovascular accident, pulmonary embolism and deep vein thrombosis within 6 months prior to enrollment.\n* Medical history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonia or interstitial lung disease; or evidence of active pneumonia detected on contrast-enhanced chest CT.\n* Any significant clinical or laboratory abnormalities judged by the investigator to compromise safety assessment, including uncontrolled active infection, poorly controlled diabetes, hypertension unresponsive to single-agent therapy, Grade ≥ 2 peripheral neuropathy, congestive heart failure, New York Heart Association (NYHA) Class ≥ II cardiac disease, myocardial infarction within 3 months prior to enrollment, unstable arrhythmia, unstable angina, chronic kidney disease and thyroid dysfunction.\n* Major surgery performed within 28 days prior to enrollment without complete postoperative recovery.\n* Active infection requiring systemic oral or intravenous treatment within 2 weeks prior to enrollment (excluding viral hepatitis and prophylactic medication).\n* Patients with active tuberculosis, or those who received anti-tuberculosis therapy within 1 year prior to enrollment.\n* For patients positive for hepatitis B surface antigen (HBsAg) and\u002For hepatitis B core antibody (HBcAb), HBV-DNA must be less than 500 IU\u002FmL. Patients with active hepatitis B must have received antiviral therapy for at least 14 days before enrollment (e.g., entecavir or tenofovir per local guidelines) and agree to continue effective antiviral treatment throughout the study. For patients positive for HCV antibody, HCV-RNA testing is required; those with HCV-RNA \\> 1000 copies\u002FmL will be excluded.\n* Positive human immunodeficiency virus (HIV) antibody.\n* Administration of any live vaccine (e.g., influenza vaccine, varicella vaccine) within 28 days prior to enrollment.\n* Prior allogeneic bone marrow transplantation or solid organ transplantation.\n* Known allergy to any study drug or its excipients.\n* History of uncorrected serum electrolyte disorders (e.g., hypokalemia, hypocalcemia, hypomagnesemia).\n* Participation in other interventional clinical studies within 28 days prior to enrollment.\n* Presence of clinically significant underlying diseases or other conditions judged by the investigator to interfere with study drug administration or protocol compliance.","70 Years",{"count":149,"type":22},[26],"This is a single-arm clinical study aiming to enroll 30 colon cancer patients with liver-only metastases. All eligible participants will undergo screening and enrollment after signing the informed consent form.\n\nAll patients will receive stereotactic body radiation therapy (SBRT) targeting 1 to 3 liver lesions (each \\\u003C 3 cm) at a total dose of 50 Gy delivered in 5 fractions. For lesions adjacent to the liver capsule, portal vein or bile duct, the target volume can be expanded by 5-10 mm outside the visible lesion boundary. One week after radiotherapy completion, patients will be treated with QL1706 (Apalitamab-Tovorizumab, 5 mg\u002Fkg, iv, Q3W) combined with CAPOX plus bevacizumab.\n\nPreoperative treatment consists of up to 6 cycles, with each cycle lasting 3 weeks. Efficacy assessment will be conducted every 2 cycles. The investigator or multidisciplinary team (MDT) will decide to initiate curative treatment (surgical resection or radiofrequency ablation of liver metastases, combined with synchronous or staged resection of primary colon lesion) or continue conversion therapy. Surgery shall be scheduled 6 weeks after the final dose of bevacizumab. During the preoperative waiting period, one extra cycle of QL1706 (5 mg\u002Fkg, iv, Q3W) plus CAPOX is permitted. The interval between the last immunochemotherapy administration and surgery is required to be 2-3 weeks.\n\nAdjuvant therapy is scheduled to start 3 weeks after surgery, and must be initiated no later than 2 months postoperatively. The investigator will determine the use of QL1706 and\u002For bevacizumab in adjuvant setting according to individual patient conditions. If the time from surgery to adjuvant therapy is less than 4 weeks, the first postoperative cycle will use QL1706 (5 mg\u002Fkg, iv, Q3W) combined with CAPOX only. Postoperative QL1706 maintenance treatment will not exceed 1 year. Patients receiving postoperative systemic adjuvant chemotherapy will complete 8 cycles of perioperative CAPOX with or without bevacizumab.\n\nPatients with progressive disease (PD) or those who fail conversion therapy within 18 weeks will switch to alternative systemic regimens in accordance with the 2025 guidelines issued by the Chinese Society of Clinical Oncology (CSCO) and the National Comprehensive Cancer Network (NCCN).\n\nCAPOX + bevacizumab regimen (repeated every 3 weeks):\n\nOxaliplatin: 130 mg\u002Fm², intravenous infusion over 2 hours, d1; Capecitabine: 1000 mg\u002Fm² per dose, po, bid, d1-14; Bevacizumab: 7.5 mg\u002Fkg, ivgtt, d1.",[32,745],"Synchronous Liver Metastases",[747,748,749,750],"QL1706","colon cancer","synchronous liver metastases","conversion","2026-06-14",{"date":753,"type":44},"2026-06-16",{"date":41,"type":22},{"date":81,"type":22},{"name":757,"class":84},"Fujian Medical University"]